Bryan Gant | White & Case LLP International Law Firm, Global Law Practice
Bryan Gant
Bryan Gant

Bryan Gant

Partner, New York

A New York lawyer with experience in antitrust litigation, and particular knowledge of the intersection of antitrust and intellectual property.

Overview

Bryan's practice focuses on complex commercial litigation and counseling, primarily in the antitrust area.

A partner in the Firm's Global Antitrust Practice based in New York, he represents clients in the pharmaceutical, financial services and petroleum sectors. Notable recent clients include Pfizer, Allergan, Boehringer Ingelheim, Experian, Novartis, OPEC and Warner Chilcott.

Bryan's knowledge and experience span a wide range of issues, including "reverse payment" settlements of patent disputes, product innovation and product retirement (so-called "product hopping"), price-fixing, fraudulent procurement of patents and other misconduct before the US Patent & Trademark Office, sham litigation, sham petitioning of the FDA, product bundling, and other antitrust theories.

Bryan is a regular contributor to Antitrust Law Developments, and a member of the Antitrust Section of the American Bar Association.

Bars and Courts

  • New York State Bar
  • US District Court for the Eastern District of New York
  • US District Court for the Southern District of New York
  • US Court of Appeals for the Second Circuit
  • US Court of Appeals for the Eighth Circuit

Education

  • JD, University of Chicago Law School
  • BA, Winthrop University

Languages

  • English

Experience

Representing Pfizer, Inc. in ground-breaking litigation challenging Johnson & Johnson's efforts to deter biosimilar competition in respect of its blockbuster biologic Remicade.

Representing Pfizer in class action litigation accusing the company of delaying entry of generic competition to Lipitor, the largest-selling pharmaceutical of all time. The asserted claims include misconduct before the US Patent and Trademark Office, and an alleged "reverse payment" patent settlement.

Representing Wyeth Pharmaceuticals in class action litigation alleging delayed generic competition to Effexor XR, a blockbuster antidepressant medication. Claims include misconduct before the US Patent and Trademark Office, and an alleged "reverse payment" patent settlement.

Representing a generic pharmaceutical manufacturer in class action litigation alleging price-fixing related to generic pharmaceuticals. White & Case obtained dismissal of all claims against its client in this matter.

Representing Warner Chilcott (now owned by Allergan) in class action litigation alleging a reverse payment settlement, misconduct before the US Patent and Trademark Office, and alleged "product hopping" regarding the oral contraceptive Loestrin.

Representing a cybersecurity vendor in claims brought by a cybersecurity testing firm regarding an alleged group boycott against cybersecurity testers.

Represented OPEC (the Organization of the Petroleum Exporting Countries) in several litigations seeking to challenge OPEC's activities under U.S. antitrust law, securing dismissal of all claims.

Represented Experian Information Solutions, Inc. in an action brought by FICO the dominant provider of consumer credit risk scoring services, against the three major U.S. credit bureaus alleging collusion and trademark violations in the sale of credit scoring services, securing summary judgment on the antitrust claims and a jury verdict on the trademark claims. The jury also found that FICO committed fraud on the U. S. Patent and Trademark Office in procuring registration of the trademark in suit.

Represented Novartis Pharmaceuticals Corporation in class action litigation accusing sixteen major international pharmaceutical companies and the largest U.S. pharmaceutical wholesalers of a group boycott in violation of the antitrust laws, securing dismissal of all claims.

Speaking Engagements

2016 Fordham Competition Law Institute, Panelist: Economics Workshop Session A: Choosing and Hiring an Economic Expert

Publications

  • Understanding Actavis: How Courts Misinterpret FTC v. Actavis, Inc., and How to Get It Right, 22 Harv. Neg. L.R. 111, Fall 2016
  • European Union Blocks Merger of NYSE Euronext and Deutsche Bӧrse AG, The Exchange newsletter, published by the Insurance and Financial Services Committee of the ABA Antitrust Section, Fall 2012, (co-author with S. Lynn Diamond)